Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 5/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533922 | 0.92 | PTGDR2 (0.49) | PTGDR2EPHX2CETPMRGPRX4EIF4EBP1 | |
| SCHEMBL534686 | 0.90 | PTGDR2 (0.49) | PTGDR2KMT2ACETPHPGDKDM4E | |
| SCHEMBL534580 | 0.87 | MRGPRX4 (0.35) | PTGDR2EPHX2KMT2ACETPHPGD | |
| SCHEMBL3781705 | 0.85 | PTGDR2 (0.48) | PTGDR2KMT2AHPGDKDM4EMAPT | |
| SCHEMBL3777093 | 0.84 | PTGDR2 (0.52) | PTGDR2KMT2AHPGDKDM4EMAPT | |
| SCHEMBL534010 | 0.84 | PTGDR2 (0.32) | PTGDR2EPHX2MAPTLMNA | |
| SCHEMBL534009 | 0.84 | PTGDR2 (0.32) | PTGDR2EPHX2KDM4EMAPTLMNA | |
| SCHEMBL3776143 | 0.83 | PTGDR2 (0.51) | PTGDR2KMT2AHPGDKDM4EMAPT | |
| SCHEMBL3772684 | 0.82 | PTGDR2 (0.54) | PTGDR2KMT2AKDM4EMAPTLMNA | |
| SCHEMBL534813 | 0.82 | PTGDR2 (0.58) | PTGDR2KMT2ACETPKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | PTGDR2 75/4885EPHX2 1648/4885KMT2A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.